Mutant p53 reactivation restricts the protumorigenic consequences of wild type p53 loss of heterozygosity in Li-Fraumeni syndrome patient-derived fibroblasts

Himanshi Agarwal,Perry Tal,Naomi Goldfinger,Esita Chattopadhyay,David Malkin,Varda Rotter,Ayush Attery

DOI: https://doi.org/10.1038/s41418-024-01307-4

IF: 12.067

2024-05-15

Cell Death and Differentiation

Abstract:The p53 tumor suppressor, encoded by the TP53 gene, serves as a major barrier against malignant transformation. Patients with Li-Fraumeni syndrome (LFS) inherit a mutated TP53 allele from one parent and a wild-type TP53 allele from the other. Subsequently, the wild-type allele is lost and only the mutant TP53 allele remains. This process, which is termed loss of heterozygosity (LOH), results in only mutant p53 protein expression. We used primary dermal fibroblasts from LFS patients carrying the hotspot p53 gain-of-function pathogenic variant, R248Q to study the LOH process and characterize alterations in various pathways before and after LOH. We previously described the derivation of mutant p53 reactivating peptides, designated pCAPs (p53 Conformation Activating Peptides). In this study, we tested the effect of lead peptide pCAP-250 on LOH and on its associated cellular changes. We report that treatment of LFS fibroblasts with pCAP-250 prevents the accumulation of mutant p53 protein, inhibits LOH, and alleviates its cellular consequences. Furthermore, prolonged treatment with pCAP-250 significantly reduces DNA damage and restores long-term genomic stability. pCAPs may thus be contemplated as a potential preventive treatment to prevent or delay early onset cancer in carriers of mutant p53.

biochemistry & molecular biology,cell biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the pro - tumorigenic consequences caused by the loss of heterozygosity (LOH) of the wild - type p53 gene in patients with Li - Fraumeni syndrome (LFS). Specifically, LFS patients carry one mutated TP53 allele and one wild - type TP53 allele. As cells are passaged in culture, the wild - type TP53 allele is gradually lost, leaving only the mutated TP53 allele, a process known as LOH. LOH leads to the accumulation of mutated p53 protein, increased DNA damage, enhanced cell metabolism, and may accelerate cell senescence. These changes work together to promote tumor development. The focus of the paper's research is to re - activate the mutated p53 protein by using a short peptide named pCAP - 250, thereby inhibiting the LOH process and its related pro - tumor effects. The research results show that pCAP - 250 can effectively inhibit the expression of mutated p53, reduce DNA damage, restore long - term genomic stability, and significantly reduce the cell proliferation rate in late - passage LFS fibroblasts, indicating that pCAP - 250 may be a potential treatment method for preventing or delaying the early occurrence of cancer in LFS mutation carriers.

Mutant p53 reactivation restricts the protumorigenic consequences of wild type p53 loss of heterozygosity in Li-Fraumeni syndrome patient-derived fibroblasts

Abstract 2988: Loss of Rbm38 Cooperates with Mutant P53 to Promote Lymphomagenesis Through Downregulation of Pten

Inhibition of nonsense-mediated decay rescues p53/ isoform expression and activates the p53 pathway in and select-mutant cancers

The Function of a Heterozygous P53 Mutation in a Li-Fraumeni Syndrome Patient.

tp53 R217H and R242H Mutant Zebrafish Exhibit Dysfunctional p53 Hallmarks and Recapitulate Li-Fraumeni Syndrome Phenotypes

Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome

Reducing Fatty Acid Oxidation Improves Cancer-free Survival in a Mouse Model of Li-Fraumeni Syndrome

Modeling the Etiology of p53-mutated Cancer Cells

Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway

[Advances on Mutant P53 Research].

Abstract 1533: Characterizing tumor-immune surveillance in Li-Fraumeni syndrome

Targeting mutant p53-R248W reactivates WT p53 function and alters the onco-metabolic profile

Molecular insights into TP53 mutation (p. Arg267Trp) and its connection to Choroid Plexus Carcinomas and Li-Fraumeni Syndrome

Abstract 6198: TP53 mutational clusters stratify the Li-Fraumeni syndrome spectrum

Mutant p53 as a guardian of the cancer cell

Germline p.R181H variant in TP53 in a family exemplifying the genotype-phenotype correlations in Li-Fraumeni syndrome

Rewired m6A epitranscriptomic networks link mutant p53 to neoplastic transformation

DNA repair processes are critical mediators of p53-dependent tumor suppression

Dominant-negative TP53 mutations potentiated by the HSF1-regulated proteostasis network

Targeting mutant p53 for cancer therapy: direct and indirect strategies

Proteasome inhibition paradoxically degrades gain-of-function mutant p53 R273H in NSCLC and could have therapeutic implications